Screening for hepatocellular carcinoma: good enough but best yet to come.
Amarapurkar
Deepak
D
D000553:Ambulatory Care; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000191:economics / Q000401:mortality / Q000628:therapy / Q000821:virology; D003362:Cost-Benefit Analysis; D019694:Hepatitis B, Chronic / Q000150:complications; D017721:Hospital Costs; D006784:Hospitals, Teaching; D006801:Humans; D015994:Incidence; D008099:Liver / Q000000981:diagnostic imaging* / Q000821:virology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000821:virology; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000191:economics / Q000401:mortality / Q000628:therapy / Q000821:virology; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D010348:Patient Care Team; D011237:Predictive Value of Tests; D011379:Prognosis; D013997:Time Factors; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis*
C097353:AFP protein, human; D000509:alpha-Fetoproteins